The pain we built this for
If you run a drug-safety or pharmacovigilance operation, the math is against you: “Case volume climbs 20–30% a year, every ICSR is a regulatory clock, our narrative quality is reviewer-dependent, and the one thing we cannot ship is a hallucinated adverse-event fact — so we can’t just point an LLM at it.”
- ICSR volume grows every year while headcount does not — intake, triage, coding, and narrative writing all compete for the same reviewers against the same regulatory clock.
- A generic LLM is disqualified on day one: a single hallucinated causality or seriousness statement in a safety narrative is not a bug, it is a compliance event.
- Signals hide in the case series. By the time manual triage clusters the related reports, the pattern is weeks old.
- 2026 FDA and EMA guidance expects AI in safety workflows to be explainable, validated, human-in-the-loop, and inspection-ready — not a black box that files on its own.
- You cannot send patient narratives or proprietary signal data to a third-party AI API — so most "AI PV" offerings are off the table before the first demo.